Can you make notes on heart pathology micro pharma medicine and surgery
Asking for Preferences
Which heart conditions should the notes cover? · What level are these notes for? · Preferred format?
Make overall notes from top to bottom from 1st year to final year topic all in one roof
Reading File
Finding Sources
Finding Sources
Good. I can see dedicated cardiology textbooks. Let me now do parallel searches across all the major heart topics.
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Excellent - I have the Robbins pathology file with great MI/angina content. Now let me pull more detailed content from multiple topics in parallel.
Reading File
Reading File
Finding Sources
I have excellent pathology content from Robbins. Now let me pull the detailed MI pathology, valvular disease, and heart failure management content in parallel.
Reading File
Reading File
Finding Sources
I now have rich content from Robbins pathology on MI morphology. Let me pull heart failure management and valvular disease content, plus CABG surgery notes.
Reading File
Reading File
I now have comprehensive content. Let me get the valvular disease and heart failure sections, plus microbiology (infective endocarditis) to round out the notes.
Reading File
Reading File
I now have enough rich content to compile comprehensive notes. Let me also grab valvular disease from Robbins and infective endocarditis content quickly.
Reading File
I now have comprehensive content from Robbins pathology. Let me compile the full notes now.---
COMPREHENSIVE HEART NOTES
From 1st Year to Final Year - Pathology | Microbiology | Pharmacology | Medicine | Surgery
PART 1: ANATOMY & HISTOLOGY (1st Year)
Cardiac Histology (Junqueira's Basic Histology)
- Cardiac muscle: Involuntary striated muscle, branching fibers connected by intercalated discs
- Intercalated discs contain:
- Fascia adherens - mechanical attachment (most of disc)
- Desmosomes - mechanical coupling
- Gap junctions (nexus) - electrical coupling, allows syncytium function
- Myocyte features: single central nucleus, T-tubules at Z-line level, abundant mitochondria (30-35% cell volume)
- Purkinje fibers (conduction system): large pale cells, rich in glycogen, sparse myofibrils
Coronary Anatomy (Bailey & Love; Gray's Anatomy)
| Vessel | Territory Supplied |
|---|---|
| Left main stem (LMS) | Splits into LAD + Cx |
| LAD (Left Anterior Descending) | Anterior LV, anterior 2/3 septum, apex |
| Circumflex (Cx) | Lateral LV, SA node in 40% |
| Right Coronary Artery (RCA) | RV, SA node (60%), AV node (90%) |
- Right dominance (90%): RCA supplies posterior descending artery (PDA)
- Left dominance (10%): Cx supplies PDA
- LAD is the most frequently diseased and most often bypassed artery
PART 2: PHYSIOLOGY (1st Year)
Cardiac Action Potential
- Phase 0 - Rapid depolarization (Na+ in)
- Phase 1 - Early repolarization (K+ out, Cl- in)
- Phase 2 - Plateau (Ca2+ in via L-type channels, K+ out)
- Phase 3 - Rapid repolarization (K+ out)
- Phase 4 - Resting potential (pacemaker cells show slow depolarization)
Starling's Law
- Increased preload → increased stretch → increased stroke volume
- Failing heart: operates on descending limb of Starling curve
Myocardial Infarction Physiology (Guyton & Hall; Ganong's)
- Within seconds of occlusion: aerobic metabolism ceases → ATP drops → lactic acid accumulates
- Reversible injury: up to ~20 minutes
- Irreversible injury: >20-40 minutes → coagulative necrosis
- Early death: 80-90% due to ventricular fibrillation (myocardial irritability), not mechanical failure
- "Stunned myocardium" - post-reperfusion noncontractile but viable state
PART 3: PATHOLOGY - HEART (Robbins & Kumar; Robbins Cotran)
(This is the core exam section)
3A. Ischemic Heart Disease (IHD)
Atherosclerosis & Plaque
- Underlying cause of IHD in >90% cases
- Stable plaque: fibrous cap intact, luminal obstruction >70% needed to cause stable angina
- Vulnerable plaque: thin cap, large lipid core, > rupture risk; most MIs arise from plaques with <70% stenosis
- Plaque rupture → subendothelial collagen exposed → platelet adhesion → TXA2/ADP/serotonin → aggregation/vasospasm → thrombus → occlusion
Angina Pectoris
| Type | Mechanism | Relief |
|---|---|---|
| Stable | Atherosclerotic stenosis + increased demand | Rest, nitrates |
| Unstable | Plaque disruption + non-occlusive thrombus | Aggressive treatment required |
| Prinzmetal/Variant | Coronary vasospasm (can occur in normal vessels) | Nitrates, Ca2+ channel blockers |
Myocardial Infarction (MI)
Definition: "Presence of acute myocardial injury detected by abnormal cardiac biomarkers in the setting of acute myocardial ischemia" (2018 ESC/ACC joint task force)
Epidemiology: 10% before age 40; 45% before age 65; men > women until menopause
Pathogenesis Sequence:
- Plaque erosion/disruption
- Platelet adhesion (collagen, vWF)
- Platelet activation → TXA2, ADP, serotonin
- Coagulation activation (tissue factor)
- Complete thrombotic occlusion within minutes
Types by depth:
- STEMI (Transmural): full thickness, occluded artery
- NSTEMI (Subendocardial): innermost layer, partial/no occlusion
Morphologic Evolution - THE KEY TABLE:
| Time | Gross | Microscopy |
|---|---|---|
| 0-30 min | None | None (EM: myofibril relaxation, glycogen loss, mitochondrial swelling) |
| 30 min-4 hrs | None | Wavy fiber change at borders; sarcolemmal disruption |
| 4-12 hrs | Occasional dark mottling | Onset coagulation necrosis; edema; hemorrhage |
| 12-24 hrs | Dark mottling | Coagulation necrosis; nuclear pyknosis; hypereosinophilic myocytes; marginal contraction band necrosis; early neutrophilic infiltrate |
| 1-3 days | Yellow-tan center | Coagulation necrosis; loss of nuclei/striations; neutrophil infiltrate peaks |
| 3-7 days | Hyperemic border; yellow-tan soft center | Neutrophil death; macrophage phagocytosis begins at border |
| 7-10 days | Maximally yellow-tan, soft; depressed red-tan margins | Well-developed macrophage phagocytosis; early granulation tissue at margins |
| 10-14 days | Red-gray depressed borders | Granulation tissue with new vessels + collagen deposition |
| 2-8 weeks | Gray-white scar | Increased collagen, decreased cellularity |
| >2 months | Scar complete | Dense collagenous scar |
Cardiac Biomarkers:
- Troponin I/T: rise at 3-4 hrs, peak 12-24 hrs, elevated for 7-14 days (most specific/sensitive)
- CK-MB: rise at 4-8 hrs, peak 12-24 hrs, normalizes at 48-72 hrs (useful for re-infarction)
- Myoglobin: earliest (1-2 hrs), not specific
- LDH: late marker, elevated up to 7 days
Complications of MI:
| Complication | Timing | Notes |
|---|---|---|
| Arrhythmia | First 24-48 hrs | Most common cause of early death; VF most lethal |
| Cardiogenic shock | First days | >40% LV infarction; mortality 70-90% |
| LV free wall rupture | 3-7 days | Massive hemopericardium → tamponade; "catastrophic" |
| Papillary muscle rupture | 3-7 days | Acute MR; posterior papillary muscle more vulnerable (single blood supply) |
| Ventricular septal defect | 3-7 days | New harsh pansystolic murmur |
| Pericarditis (epistenocardiac) | 2-3 days | Friction rub; anterior chest pain |
| Mural thrombus | Days-weeks | Risk of systemic embolism |
| Ventricular aneurysm | Weeks-months | Anteroseptal scar; persistent ST elevation on ECG |
| Dressler syndrome | 2-10 weeks | Autoimmune pericarditis; antibodies to myocardium |
3B. Hypertensive Heart Disease
- Left-sided: LV hypertrophy (concentric) - heart weight >500g, LV wall >2cm
- Microscopy: increased myocyte diameter, "boxcar nuclei" (enlarged hyperchromatic), intercellular fibrosis
- Clinical: initially asymptomatic → atrial fibrillation (from LA dilation) → diastolic dysfunction → CHF
- Right-sided (Cor Pulmonale): RVH due to pulmonary hypertension (COPD most common cause in West)
3C. Valvular Heart Disease
| Valve Lesion | Key Etiology | Murmur | Key Features |
|---|---|---|---|
| Mitral Stenosis | Rheumatic fever | Mid-diastolic (opening snap) | LA dilation, pulmonary hypertension, AF |
| Mitral Regurgitation | Ischemia, MVP, rheumatic, IE | Pansystolic at apex | Volume overload; LA + LV dilate |
| Aortic Stenosis | Calcific degeneration, congenital bicuspid aortic valve, rheumatic | Ejection systolic; radiates to carotids | Triad: angina, syncope, HF; gradient >40 = severe |
| Aortic Regurgitation | Rheumatic, IE, Marfan, syphilitic aortitis | Early diastolic (decrescendo) | Wide pulse pressure; collapsing/water-hammer pulse |
| MVP | Myxomatous degeneration | Midsystolic click + late systolic murmur | Young women; risk of MR, IE, arrhythmia |
Rheumatic Heart Disease:
- Group A Strep (GAS) pharyngitis → molecular mimicry → cross-reactive Ab against cardiac tissue
- Aschoff bodies: pathognomonic; granulomatous lesions with Aschoff cells (modified macrophages with "owl eye" nuclei), surrounded by lymphocytes
- Anitschkow cells: caterpillar cells (distinctive macrophages)
- Valves affected in order: M > A > T > P (mitral most common)
- Acute: pancarditis (endocarditis with MacCallum patches on LA, myocarditis, pericarditis)
- Chronic: fibrosis + calcification → stenosis ("fish mouth" or "button hole" mitral stenosis)
Infective Endocarditis (IE):
- Acute IE: S. aureus most common; virulent organism; normal valve; destructive vegetations
- Subacute IE (SBE): S. viridans most common; low virulence; damaged/abnormal valve; smaller vegetations
- Other organisms: Enterococcus, S. bovis (colon cancer!), HACEK group, Candida
- IVDU: tricuspid valve most common; S. aureus
- Vegetations: friable, irregular, on valve cusps; contain organisms + fibrin + platelets
- Complications: valve destruction, septic emboli (kidney infarcts, splenic infarcts, brain abscess), immune complex glomerulonephritis
- Duke Criteria: 2 major OR 1 major + 3 minor OR 5 minor = definite IE
- Major: positive blood cultures (×2), positive echo (vegetation/abscess/new regurgitation)
- Minor: fever >38°C, vascular phenomena (Janeway lesions), immunologic phenomena (Osler nodes, Roth spots, +RF), predisposing condition
3D. Cardiomyopathies
| Type | Morphology | Cause | Key Features |
|---|---|---|---|
| Dilated (DCM) | LV + RV dilated; thin walls | Idiopathic (50%), alcohol, viral (Coxsackie B), peripartum, drugs (Doxorubicin) | Systolic failure; 4-chamber dilation; mural thrombi |
| Hypertrophic (HCM) | Asymmetric septal hypertrophy; banana-shaped LV | AD; sarcomere protein mutations (MYH7, MYBPC3) | Diastolic failure; LVOTO; sudden death in young athletes |
| Restrictive | Stiff, non-compliant walls; normal wall thickness | Amyloidosis, sarcoidosis, haemochromatosis, endomyocardial fibrosis | Diastolic failure; mimics constrictive pericarditis |
| Arrhythmogenic RV | Fibrofatty replacement of RV | PKP2 mutation (desmosome) | Right-sided HF; VT; sudden death in young |
HCM Key Points:
- Microscopically: myocyte disarray (whorled pattern), fibrosis
- LVOTO due to systolic anterior motion (SAM) of mitral valve
- Murmur: harsh ejection systolic; decreases with squatting/handgrip; increases with Valsalva/standing
3E. Pericardial Disease
| Condition | Features |
|---|---|
| Fibrinous pericarditis | Bread-and-butter appearance; friction rub; post-MI, uraemia, RF |
| Serous pericarditis | Clear fluid; viral, SLE |
| Haemopericardium | Blood in pericardium; trauma, MI rupture, aortic dissection |
| Cardiac tamponade | Beck's triad: hypotension, muffled heart sounds, elevated JVP; pulsus paradoxus |
| Constrictive pericarditis | Obliterated pericardial space; TB most common worldwide; calcified pericardium on CXR |
PART 4: MICROBIOLOGY (2nd Year)
Organisms in Heart Disease
| Organism | Disease | Notes |
|---|---|---|
| Streptococcus pyogenes (GAS) | Rheumatic fever → RHD | M-protein cross-reactive with cardiac antigens |
| Streptococcus viridans | Subacute bacterial endocarditis | Most common SBE after dental procedures |
| S. aureus | Acute endocarditis; IVDU | Coagulase positive; produces toxins |
| S. bovis (S. gallolyticus) | SBE | Always screen for colorectal cancer |
| Enterococcus faecalis | Endocarditis | GI/GU procedures; resistant strains (VRE) |
| Coxsackievirus B | Viral myocarditis → DCM | B3, B4; most common viral cause |
| Treponema pallidum | Syphilitic aortitis | Obliterative endarteritis of vasa vasorum; aortic regurgitation |
| Trypanosoma cruzi | Chagas disease → myocarditis | South America; apical aneurysm; megaoesophagus |
| Diphtheria (C. diphtheriae) | Myocarditis (toxin-mediated) | Heart block; arrhythmia; exotoxin inhibits protein synthesis |
| Borrelia burgdorferi | Lyme carditis | AV block; tick bite |
| HACEK group | Subacute endocarditis | Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella |
PART 5: PHARMACOLOGY (2nd-3rd Year)
5A. Antianginal Drugs
| Drug Class | Examples | Mechanism | Side Effects |
|---|---|---|---|
| Nitrates | GTN, ISDN, ISMN | NO → ↑cGMP → vasodilation (venous >> arterial); ↓preload | Headache, tolerance, hypotension |
| Beta-blockers | Metoprolol, Atenolol, Carvedilol | Block β1 → ↓HR, ↓contractility, ↓O2 demand | Bradycardia, bronchospasm, fatigue |
| Calcium channel blockers | Amlodipine (DHP), Verapamil, Diltiazem | Block L-type Ca2+ channels | Amlodipine: oedema, flushing; Verapamil: constipation, AV block |
| Ivabradine | - | Blocks If "funny current" in SA node → ↓HR only | Not for ACS; use if BB intolerant |
| Ranolazine | - | Inhibits late Na+ current → ↓Ca2+ overload | QT prolongation |
5B. Antihypertensive Drugs
| Class | Drug | Mechanism | Indication/Notes |
|---|---|---|---|
| ACE Inhibitors | Ramipril, Enalapril, Lisinopril | Block ACE → ↓Angiotensin II → vasodilation + ↓aldosterone | Preferred in DM, post-MI, HFrEF, CKD; SE: dry cough, angioedema; CI: pregnancy |
| ARBs | Losartan, Valsartan, Candesartan | Block AT1 receptor | Use if ACEi cough; same cardiac benefit |
| Beta-blockers | Metoprolol, Bisoprolol, Carvedilol | ↓HR, ↓renin | Post-MI, HF, angina, AF rate control |
| Dihydropyridine CCBs | Amlodipine, Nifedipine | Block Ca2+ in vascular smooth muscle → vasodilation | First-line; good in elderly, Afro-Caribbean |
| Non-DHP CCBs | Verapamil, Diltiazem | Block Ca2+ in heart + vessels | Rate control in AF; avoid with BB |
| Thiazide diuretics | Indapamide, HCTZ | Block NCC in DCT → ↓Na+/water | First-line alone or in combination; SE: hypoK+, hyperuricaemia, hyperglycaemia |
| Aldosterone antagonists | Spironolactone, Eplerenone | Block aldosterone receptor | Post-MI with HF; resistant hypertension |
5C. Heart Failure Drugs
| Class | Drug | Evidence/Benefit |
|---|---|---|
| ACE inhibitors | Ramipril (AIRE trial), Enalapril | Reduce mortality; first-line |
| Beta-blockers | Bisoprolol (CIBIS-II), Carvedilol, Metoprolol | Reduce mortality; start at low dose; uptitrate |
| MRA (Aldosterone antagonists) | Spironolactone, Eplerenone | Reduce mortality (RALES, EPHESUS trials) |
| SGLT2 inhibitors | Dapagliflozin, Empagliflozin | Reduce hospitalisation + mortality in HFrEF and HFpEF |
| ARNI | Sacubitril/Valsartan (LCZ696) | Superior to enalapril in PARADIGM-HF; combine ARB + neprilysin inhibitor |
| Loop diuretics | Furosemide | Symptom relief; ↓congestion; no mortality benefit |
| Digoxin | Digoxin | ↑contractility; rate control in AF; narrow TI; toxicity: nausea, visual disturbance, arrhythmia |
| Ivabradine | Ivabradine | ↓HR in sinus rhythm; add-on if HR >70 bpm |
5D. Antiarrhythmic Drugs (Vaughan-Williams Classification)
| Class | Examples | Channel Blocked | Use |
|---|---|---|---|
| Ia | Quinidine, Procainamide | Na+ (moderate); also K+ | VT, AF (less used now) |
| Ib | Lignocaine (Lidocaine) | Na+ (fast off) | Acute VT/VF post-MI; IV only |
| Ic | Flecainide, Propafenone | Na+ (slow off) | AF/SVT; CI post-MI (CAST trial) |
| II | Metoprolol, Atenolol | β-adrenergic | AF rate control; SVT; post-MI |
| III | Amiodarone, Sotalol | K+ | AF/VT/VF (Amiodarone - broadest spectrum); Sotalol also has β-block |
| IV | Verapamil, Diltiazem | Ca2+ | SVT rate control; CI in AF+WPW |
| Other | Adenosine | A1 receptor → ↑K+ | Acute termination of SVT; very short action |
| Other | Digoxin | Na/K ATPase | AF rate control |
Amiodarone toxicities: Thyroid (hypo/hyper), pulmonary fibrosis, hepatotoxicity, corneal micro-deposits, photosensitivity, peripheral neuropathy, blue-grey skin discolouration.
5E. Anticoagulation in Cardiac Disease
| Drug | Mechanism | Use in Cardiology |
|---|---|---|
| Heparin (UFH) | Activates ATIII → inhibits Xa + IIa | ACS (STEMI/NSTEMI), PE, DVT |
| LMWH (Enoxaparin) | Mainly anti-Xa | NSTEMI; more predictable than UFH |
| Warfarin | Inhibits Vit K reductase → ↓II, VII, IX, X | AF; prosthetic valves; DVT/PE |
| DOACs (Dabigatran) | Direct thrombin inhibitor | AF (non-valvular); DVT/PE |
| DOACs (Rivaroxaban, Apixaban) | Direct Xa inhibitors | AF; ACS (low dose); DVT/PE |
| Aspirin | Irreversible COX-1 inhibition → ↓TXA2 | ACS; post-MI; CABG |
| Clopidogrel/Ticagrelor | P2Y12 inhibitor → ↓ADP-mediated platelet aggregation | ACS; post-PCI (dual antiplatelet) |
PART 6: MEDICINE - CLINICAL CARDIOLOGY (3rd-4th Year)
6A. Acute Coronary Syndrome (ACS)
Classification:
- STEMI: ST elevation + raised troponin → complete coronary occlusion
- NSTEMI: No ST elevation + raised troponin → partial occlusion
- Unstable Angina: No ST elevation + normal troponin
STEMI ECG Changes by Territory:
| Territory | ECG leads | Artery |
|---|---|---|
| Anterior | V1-V4 | LAD |
| Anterolateral | V4-V6, I, aVL | LAD/Cx |
| Inferior | II, III, aVF | RCA (90%) |
| Posterior | ST depression V1-V2; tall R waves | RCA/Cx |
| Lateral | I, aVL, V5-V6 | Cx |
STEMI Management (MONA + reperfusion):
- Primary PCI within 90 min (preferred if available)
- If PCI not available within 120 min: Thrombolysis (alteplase, streptokinase)
- Antiplatelet: Aspirin 300mg + Ticagrelor/Clopidogrel (DAPT)
- Anticoagulation: Heparin/LMWH/fondaparinux
- MONA: Morphine, Oxygen (only if SpO2 <94%), Nitrates, Aspirin
- Post-MI: ACEi + Beta-blocker + Statin (high intensity) + DAPT
NSTEMI/UA Management (GRACE score to stratify):
- Conservative vs. early invasive strategy
- DAPT + Anticoagulant (LMWH preferred)
- Coronary angiography ± PCI within 24-72 hrs in high-risk
6B. Heart Failure
Classification:
- HFrEF (EF <40%): systolic failure; dilated, weakly contracting LV
- HFpEF (EF ≥50%): diastolic failure; stiff, non-compliant LV; common in elderly, hypertension, DM
NYHA Classification:
| Class | Symptoms |
|---|---|
| I | No symptoms with ordinary activity |
| II | Slight limitation; symptoms with moderate exertion |
| III | Marked limitation; symptoms with minimal exertion |
| IV | Symptoms at rest |
Clinical Features:
- Left heart failure: orthopnoea, PND, pulmonary oedema, fine bilateral basal crackles, S3 gallop
- Right heart failure: JVP raised, peripheral oedema, hepatomegaly, ascites
- Congestive HF: both
Investigation:
- BNP/NT-proBNP: excellent screening (elevated in HF)
- Echocardiography: gold standard (EF, wall motion, valve function)
- CXR: cardiomegaly (CTR >0.5), alveolar oedema, Kerley B lines, pleural effusion, upper lobe diversion
- ECG: LVH, AF, LBBB (marker of poor prognosis)
Acute Pulmonary Oedema Treatment:
- Position: sit upright
- O2 (high-flow or CPAP/BiPAP)
- IV Furosemide (40-80mg)
- IV Nitrates (GTN infusion) - reduce preload
- Morphine (reduces anxiety; vasodilation) - use cautiously
- Inotropes (Dobutamine) if cardiogenic shock
Chronic HFrEF Treatment (Evidence-based):
- ACE inhibitor (or ARNI if tolerated)
- Beta-blocker (Bisoprolol/Carvedilol)
- MRA (Spironolactone/Eplerenone)
- SGLT2 inhibitor (Dapagliflozin/Empagliflozin)
- Loop diuretic for symptoms (Furosemide)
- Ivabradine if HR >70 on max BB
- Device therapy: ICD (if EF <35%, NYHA II-III), CRT (if LBBB + EF <35%)
6C. Atrial Fibrillation (AF)
- Mechanism: Multiple re-entrant circuits in atria (often from pulmonary vein foci)
- Risk factors: Hypertension (most common), IHD, valvular disease, hyperthyroidism, alcohol ("holiday heart"), age
ECG: Irregularly irregular rhythm; absent P waves; fibrillatory baseline; variable ventricular rate
Classification: Paroxysmal (self-terminating <7d) / Persistent (>7d) / Long-standing persistent / Permanent
Complications: Stroke (most feared); heart failure; tachycardia-induced cardiomyopathy
CHA2DS2-VASc Score (for anticoagulation decision):
- C: HF (1), H: HTN (1), A2: Age ≥75 (2), D: DM (1), S2: Stroke/TIA (2), V: Vascular disease (1), A: Age 65-74 (1), Sc: Sex (female +1)
- Score ≥2 (male) or ≥3 (female) → anticoagulate with DOAC
Rate vs. Rhythm Control:
- Rate control first (BB or non-DHP CCB)
- Rhythm control: DC cardioversion; chemical (Flecainide, Amiodarone); Catheter ablation
6D. Valvular Heart Disease (Clinical)
Aortic Stenosis:
- Triad: Angina → Syncope → (heart) Failure (ASF - survival worsens in this order)
- Narrow pulse pressure; slow-rising carotid pulse; ejection systolic murmur
- Severe: peak gradient >40 mmHg; valve area <1 cm2
- Treatment: TAVI (transcatheter) for high surgical risk; AVR (surgical) for suitable patients
Mitral Stenosis:
- Opening snap + mid-diastolic rumble with presystolic accentuation
- Complications: AF, pulmonary hypertension, right heart failure, systemic emboli
- Treatment: Balloon mitral valvuloplasty (if pliable, non-calcified); surgical commissurotomy/replacement
PART 7: SURGERY - CARDIAC SURGERY (Final Year)
7A. Coronary Artery Bypass Grafting (CABG)
(Bailey & Love; Sabiston Surgery)
Indications:
- Left main stem (LMS) disease >50% stenosis
- Triple vessel disease (especially with LV dysfunction)
- Triple vessel disease + diabetes
- Failed PCI / unsuitable anatomy for PCI
- Angina refractory to medical therapy
Conduits:
| Conduit | Patency | Notes |
|---|---|---|
| Internal Mammary Artery (IMA) - Left | 90% at 10 years | Gold standard; preferred for LAD |
| Radial Artery | 80-85% at 5 years | Second arterial conduit |
| Long Saphenous Vein (LSV) | 50-60% at 10 years | Occlusion due to intimal hyperplasia; still widely used |
Technique:
- Most common: midline sternotomy + cardiopulmonary bypass (CPB)
- CPB ("heart-lung machine"): oxygenates blood, keeps circulation going
- Heart arrested with cardioplegia solution (high K+, cold)
- Distal anastomoses first, then proximal to aorta
- Off-pump CABG: beating heart surgery (OPCAB) - fewer CPB complications but technically harder
CPB Complications:
- Coagulopathy, infection, air embolism
- GI complications (ischaemia/pancreatitis)
- Microembolisation (brain, eyes)
- Postcardiotomy syndrome (Dressler-like)
- Neurological dysfunction
- Pulmonary injury
CABG vs. PCI (key randomised trials):
- SYNTAX trial: CABG better for complex 3-vessel/LMS disease (high SYNTAX score)
- FREEDOM trial: CABG superior to PCI in diabetics with multivessel disease
- CABG remains gold standard for LMS, 3-vessel disease, DM, complex anatomy
7B. Valve Surgery
| Procedure | Indication | Notes |
|---|---|---|
| Aortic Valve Replacement (AVR) | Severe AS (symptomatic) or severe AR with LV dysfunction | Mechanical (lifelong warfarin) or bioprosthetic (no anticoag, but re-op needed) |
| TAVI | Severe AS; high/inoperable surgical risk | Transfemoral approach commonest; dual antiplatelet post-procedure |
| Mitral Valve Repair | MR (preferred over replacement) | Better outcomes than replacement; preserve subvalvular apparatus |
| Mitral Valve Replacement | Severe MS not amenable to commissurotomy | Rheumatic disease |
| MitraClip | High-risk surgical patients with severe MR | Percutaneous leaflet approximation |
7C. Cardiac Tamponade and Pericardiocentesis
- Beck's triad: Hypotension + muffled heart sounds + elevated JVP
- Pulsus paradoxus: >10 mmHg drop in SBP on inspiration
- ECG: Electrical alternans (swinging heart in fluid)
- Treatment: Pericardiocentesis (drain pericardial effusion); subxiphoid approach; echo-guided preferred
7D. Aortic Dissection
| Type | Stanford | DeBakey | Treatment |
|---|---|---|---|
| Involves ascending aorta | Type A | I, II | Emergency surgery |
| Descending aorta only | Type B | III | Medical (beta-blockers) unless complications |
- Risk factors: Hypertension (most common), Marfan syndrome, bicuspid aortic valve, pregnancy
- Presentation: Tearing/ripping chest pain radiating to the back; pulse deficit; neurological symptoms
- Investigation: CT aortogram (gold standard)
7E. Cardiac Transplantation
- Indications: End-stage HF (EF <20-25%), NYHA IV, refractory to all medical + device therapy
- Contraindications: irreversible pulmonary hypertension, active infection, malignancy
- Rejection: Hyperacute (ABO mismatch), Acute (T-cell mediated, most common), Chronic (vasculopathy)
- Immunosuppression: Calcineurin inhibitors (Ciclosporin, Tacrolimus) + Mycophenolate + Prednisolone
PART 8: QUICK REVISION MNEMONICS
| Topic | Mnemonic |
|---|---|
| Duke criteria for IE (major) | POSITIVE Blood cultures; ECHO (vegetations/abscess) |
| Aortic stenosis triad | ASF - Angina → Syncope → Failure |
| Jones criteria for RF (major) | JONES - J: Joints (migratory polyarthritis), O: cOrditiS, N: Nodules (subcutaneous), E: Erythema marginatum, S: Sydenham's chorea |
| HF drugs with mortality benefit | A-BES: ACEi/ARNI, Beta-blockers, Eplerenone/Spironolactone, SGLT2i |
| CABG indications | LMT-D: Left main, Multivessel + DM, Triple vessel, Disabled by angina |
| Antiarrhythmics by class | Some Block Potassium Channels Adequately: Sodium (I), Beta (II), Potassium (III), Calcium (IV), Adenosine/Digoxin (V) |
| MI complications 3-7 days (rupture risks) | "Dead muscle ruptures" - VSD, papillary muscle rupture, free wall rupture |
PART 9: IMPORTANT INVESTIGATIONS SUMMARY
| Investigation | What it tells you |
|---|---|
| 12-lead ECG | MI territory, arrhythmia, LVH, PE (S1Q3T3), pericarditis (saddle-shape ST), tamponade (electrical alternans) |
| Troponin I/T | Myocyte injury; serial measurements at 0+3 or 0+6 hours |
| BNP/NT-proBNP | HF diagnosis and monitoring |
| Echocardiogram | EF, wall motion abnormalities, valve function, effusions, cardiomyopathy |
| Coronary angiogram | Gold standard for CAD - defines anatomy pre-CABG/PCI |
| CT aortogram | Aortic dissection |
| Cardiac MRI | Cardiomyopathy, viability, fibrosis (late gadolinium enhancement) |
| Holter monitor | Paroxysmal arrhythmia diagnosis |
| Exercise stress test | Ischaemia provocation; functional capacity in AS |
Sources: Robbins & Kumar Basic Pathology; Robbins Cotran Pathologic Basis of Disease; Braunwald's Heart Disease; Bailey & Love's Short Practice of Surgery; Goldman-Cecil Medicine; Family Medicine Textbook (heart failure sections); Junqueira's Basic Histology; Guyton & Hall Medical Physiology; Ganong's Review of Medical Physiology
Can you make them in easiest pattern and concept to remember and clear my confusion and concept and make it in a pdf file for me to read
Reading File
Good. I'll use ReportLab to create a beautifully formatted, easy-to-read PDF. Let me build it now.
Running Command
ls -la /tmp/workspace/ 2>/dev/null || mkdir -p /tmp/workspace && echo "created"
Running Command
mkdir -p /tmp/workspace/heart-notes && echo "done"
This is a shared conversation. Sign in to Orris to start your own chat.